Poziotinib
CAS 1092364-38-9Small Molecule
Overview
Poziotinib is a potent, orally active quinazoline-based pan-HER inhibitor targeting multiple domains within the HER family. It is primarily in development for the treatment of non-small cell lung cancer with EGFR exon 20 insertions.
Therapeutic areas
OncologyNon-Small Cell Lung Cancer
Verified Supplier Partner
Do you supply Poziotinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.